key: cord-0877768-nljimtn7 authors: Vanhove, Bernard; Marot, Stéphane; Evanno, Gwénaëlle; Malet, Isabelle; Rouvray, Gaëtane; Shneiker, Françoise; Mevel, Edwige; Ciron, Carine; Rousse, Juliette; Royer, Pierre-Joseph; Lheriteau, Elsa; Raffi, François; Duvaux, Odile; Marcelin, Anne-Geneviève; Calvez, Vincent title: Anti-SARS-CoV-2 swine glyco-humanized polyclonal antibody XAV-19 retains neutralizing activity against SARS-CoV-2 B.1.1.529 (Omicron) date: 2022-01-26 journal: bioRxiv DOI: 10.1101/2022.01.26.477856 sha: 71c21d47dc9381783ee6f58033b21354e1626f78 doc_id: 877768 cord_uid: nljimtn7 B.1.1.529 is the SARS-CoV-2 variant designated Omicron by the WHO in November 2021. It is a highly divergent variant with a high number of mutations, including 26-32 mutations in the spike protein among which 15 in the Receptor Binding Domain (RBD) including at the human angiotensin converting enzyme 2 (ACE-2) receptor interacting interface. Because of a decreased affinity for the ACE-2 receptor and a geometric reorganization of the S1-S2 cleavage site, the Omicron variant is predicted to not have a significant infectivity advantage over the delta variant and to be less pathogenic than Delta. However, in Omicron, neutralizing epitopes are greatly affected, suggesting that current vaccines and neutralizing monoclonal antibodies might confer reduced protection against this variant. In contrast, we and others previously demonstrated that polyclonal antibodies against SARS-CoV-2 RBD obtained from hyperimmunized animal hosts do maintain their neutralizing properties against Alpha to Delta. Here, we confirmed these findings by showing that XAV-19, a swine glyco-humanized polyclonal antibody retains full neutralizing activity against Omicron. Numerous neutralizing monoclonal antibodies have been developed against SARS-CoV-2. Most of them have been raised against the original Wuhan-type virus and see their neutralization potential abrogated or reduced against variants 1 , especially against the Omicron variant. To anticipate these difficulties, polyclonal antibodies (pAbs) have been produced owing to their potential to bind multiple target epitopes and to maintain their neutralizing activity even though mutations occur in the antibody binding site 2, 3 . pAbs against SARS-CoV-2 of different sources are being used in at least 10 clinical trials (Table 1 ) but clinical proof of efficacy is still partial and limited to equine globulins 4 . XAV-19 is a swine glyco-humanized polyclonal neutralizing antibody containing multiple immunoglobulins directed against a set of well-identified peptides of the Wuhan-type SARS-Cov-2 RBD protein 5 . Glyco-humanization refers to the elimination of the animal-type α1,3-Gal and Neu5GC-Gal-β-1,4 GlcNac glycosylation epitopes by the human/ape counterparts Neu5AC-Gal-β-1,4-GlcNac epitopes. This is predicted to prevent allergies and serum sickness otherwise induced in 20 to 30% of the patients receiving animal-sourced immunoglobulins 6, 7 . Glyco-humanized polyclonal antibodies are produced from pigs where genes for the glycosylation enzymes α1,3galactosyltransferase (GGTA1) and cytidine monophosphate N-acetyl hydroxylase (CMAH) have been inactivated 8 . These animals are like those recently used in xenotransplantation trials 9, 10 . Recent clinical safety data confirmed that glyco-humanized swine pAbs are well tolerated and present better pharmacokinetic properties than other pAbs 11 . We have previously described how XAV-19 binds multiple target epitopes on SARS-CoV-2 Spike and maintains neutralizing activity against the Alpha (United Kingdom/B.1.1.7), Beta (South African/B.1.351), Gamma (Brazil/P.1) and Delta (Indian/B.1.617.2) variants of concern. Here, we extended these observations to the variant Omicron (B.1.1.529). Using recombinant RBD protein of the Omicron type, we measured the neutralizing activity of XAV-19 against the Omicron ACE-2/RBD interaction in ELISA format and concluded that it is 100% conserved. In parallel the neutralization of the infectivity was confirmed in neutralization assays with live Omicron clinical isolate virus. XAV-19 is a swine glyco-humanized polyclonal antibody against SARS-CoV-2 produced by Xenothera by immunization of double knock out pigs for alpha 1,3-galactosyltransferase (GGTA1) and cytidine monophosphate N-acetyl hydroxylase (CMAH) genes, as previously described 8 . Batch-to-batch consistency is ensured by the clonal nature of the immunized animals, thereby reducing the genetic diversity, by controlling the immunization process and applying specifications on the resulting serum, before it undergoes a downstream purification process. XAV-19 used in this study was the clinical batch DP1/B07-08. Comparator Evusheld ® The binding of XAV-19 to Wuhan and Omicron RBD proteins was measured by ELISA as previously described (Vanhove et al, Front. Immunol. 2021). Briefly, recombinant RBD antigen (Sino Biological Europe, Germany) was immobilized on microtiter plate in carbonate/bicarbonate buffer pH 9.0 at 1μg/ml at 4°C for 16h. After washing and saturation with PBS-BSA-Tween, successive twofold dilutions of XAV-19 were added for 2h and washed. Porcine immunoglobulins were then revealed with a 1:1000 dilution of peroxidase-conjugated secondary antibody (Bethyl, USA). Binding intensity was revealed by addition of TMB reagent (Sigma, France) for 20 minutes, after which the reaction was stopped with 50 μl of 1M H2S04. The optical density was taken at 450 nm. Neutralization of the interaction of SARS-CoV-2 RBD with its receptor ACE-2 was also measured by ELISA as previously described 5 . Briefly, recombinant SARS-CoV-2 Spike S1-HIS proteins (Sino Biological Europe for the Wild Type Wuhan, or Omicron from Sino Biological Europe and from Covalab, France, for an alternative source of the Omicron form) were immobilized on microtiter plate in carbonate/bicarbonate buffer pH 9.0 at 1μg/ml at 4°C for 16h. After washing and saturation with PBS-BSA-Tween, successive dilutions of XAV-19 were added for 30 min, followed by ACE-2-mFc Tag ligand (Sino Biological; final concentration 125 ng/ml). After incubation for 1h at room temperature and washing, the ACE-2 mFc Tag was revealed using a peroxidase-conjugated anti-mouse secondary antibody (1:1000 dilution). Binding intensity was revealed by addition of TMB reagent (Sigma, France) for 6 min, after which the reaction was stopped with 50 μl of 1M H2S04. The optical density was taken at 450 nm. We previously determined by peptide mapping and proteolytic epitope mapping that antibodies contained in XAV-19 recognize virtually all peptides present in the Wuhan SARS-CoV-2 RBD but that the dominant target epitopes lied in 4 regions underlined in Figure 1 The binding intensities of XAV-19 against RBD Wuhan and Omicron were compared by ELISA. Although some differences appear in the profiles, the results indicated that XAV-19 binding reached the same plateau at similar concentrations (approximately 1 µg/ml). XAV-19 was tested in a RBD/ACE-2 binding competition assay, where the RBD protein was of the original Wuhan type or contained the mutations corresponding to the Omicron variant. Two independent sources of recombinant Omicron RBD were used. The dose response profiles were similar whether Wuhan or Omicron RBD were used, indicating similar full neutralization potency of XAV-19 against their interaction with ACE-2 ( Figure 3A ). In the same assay, the combination of tixagevimab and cilgavimab (Evusheld ® ) was assessed in parallel and revealed an efficacy limited to approximately 60% neutralization, whatever the dose ( Figure 3B ). target epitopes, Omicron mutations and amino acids described important for the contact with ACE-2 (as in Figure 1) , it was clear that most Omicron mutations lied mostly outside the target epitopes: changes between Wuhan and Omicron RBD represents only 3% of the main target epitopes of XAV-19 (2 changes on 53 amino acids). This might justify that binding of XAV-19 to Omicron RBD was mostly preserved. This might also justify the full neutralizing activity of XAV-19 against live SARS-CoV-2 Omicron in infection assays at equivalent to lower concentration than against other variants. Fantini et al 15 reported that Omicron presents a decreased affinity for the ACE-2 receptor, probably as a result of the alteration of several amino acids important for direct contact with ACE-2. If XAV-19 binds similarly to RBD Omicron which itself has a weaker binding to ACE-2, the model predicts that XAV-19 should present a preserved or higher neutralization potency against Omicron than against any other variant. This prediction was verified experimentally by ELISA and CPE assays on sensitive Vero E6 cells, where the IC50 were similar or even better when viral load was measured. Most monoclonal antibodies developed against SARS-CoV-2 RBD of the Wuhan form see their neutralizing efficacy abrogated or strongly impacted against the Omicron variant 16 . This is probably due to the high mutation burden in the RBD that has a high probability of impacting monoclonal antibodies target epitopes. Having multiple alternative target epitopes on the same target, as previously shown 5 Binding intensity of XAV-19 to RBD Wuhan versus Omicron. Microtiter plates have been similarly coated with Wuhan or RBD recombinant proteins. XAV-19 was added at the indicated concentration and after washing revealed with a peroxidase-conjugated secondary antibody. Optical density (means of triplicate measurements run in a single experiment) was recorded after addition of TMB reagent. Neutralization assay in the ELISA format: assessment of SARS-CoV-2 Spike/ACE-2 interaction and its XAV-19-mediated inhibition. Spike-HIS corresponding to the Wuhan or the Omicron (two different sources, as indicated) variants was immobilized on plastic and binding of recombinant human ACE2-Fc was revealed with a secondary antibody against Fc. 100% inhibition represents absence of Spike/ACE-2 interaction. A: Data are means of triplicate measurements run in a single experiment assessing XAV-19 at the indicated concentration. B: Means of triplicate measurements run in a single experiment assessing a mixture of tixagevimab and cilgavimab at the indicated global concentration. In vitro neutralization of SARS-CoV-2 variants by XAV-19. XAV-19 neutralizing potency was evaluated in an in vitro assay using whole replicating viruses. Percentage of infection was Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice Polyclonal F(ab')2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency RBD-specific polyclonal F(ab )2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial Porcine antilymphocyte globulin (p-ALG) plus cyclosporine A (CsA) treatment in acquired severe aplastic anemia: a retrospective multicenter analysis High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2 Genetically engineered pig kidney transplantation in a brain-dead human subject First pig-to-human heart transplant: what can scientists learn? Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2 Genetic and structural basis for SARS-CoV-2 variant neutralization by a twoantibody cocktail Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers The puzzling mutational landscape of the SARS-2-variant Omicron Considerable escape of SARS-CoV-2 Omicron to antibody neutralization A) and virus RNA load (B) after infection with SARS-CoV-2 viruses of the indicated variants. CPE percentage was assessed by microscopy examination and calculated on 8 replicates for each XAV-19 concentration. 100% represent absence of CPE inhibition at the studied concentration, as found in control (no inhibitor) condition. Viral load percentage was calculated as the ratio of viral XAV-19 concentrations are expressed on a 10 logarithmic scale This work was supported by Xenothera, the Agence Nationale de la Recherche sur le SIDA et The authors of this manuscript have conflicts of interest to disclose: BV, GE, GR, FS, EM, CC, JR, PJR, EL, OD are employees of Xenothera, a company developing glyco-humanized polyclonal antibodies as those described in this manuscript.